tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TuHURA Biosciences Approves Merger and Share Increase

Story Highlights
TuHURA Biosciences Approves Merger and Share Increase

Elevate Your Investing Strategy:

TuHURA Biosciences ( (HURA) ) has provided an update.

On June 23, 2025, TuHURA Biosciences held a Special Meeting where stockholders approved proposals including increasing authorized shares to 200 million and reincorporating in Delaware. The meeting also saw the election of six directors and approval of executive compensation and auditor ratification. The merger with Kineta, a clinical-stage biotechnology company, was also approved, with both companies anticipating closing the merger soon, subject to remaining conditions.

The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.

Spark’s Take on HURA Stock

According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.

TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.

To see Spark’s full report on HURA stock, click here.

More about TuHURA Biosciences

TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel technologies to overcome resistance to cancer immunotherapy. Their lead product, IFx-2.0, is designed to address primary resistance to checkpoint inhibitors and is being prepared for a Phase 3 trial as an adjunctive therapy for advanced or metastatic Merkel Cell Carcinoma.

Average Trading Volume: 169,375

Technical Sentiment Signal: Sell

Current Market Cap: $111.4M

Learn more about HURA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1